B32High rates of viral suppression sixteen weeks after transition from EFV- to DTG-based ART regardless of viral load at transition: the DO-REAL cohort study in LesothoE-posterART in first- and second-line therapies
B32The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: results from the DRIVE-AHEAD clinical trialE-posterART in first- and second-line therapies
B32Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in treatment-experienced HIV-1 infected patients: week 48 analysis from the randomized controlled phase 3 TALENT studyE-posterART in first- and second-line therapies
B32Week 96 metabolic and bone outcomes of a Phase 2b trial of islatravir and doravirineE-posterART in first- and second-line therapies
B32Achievement of undetectable HIV-1 RNA in the B/F/TAF treatment-naïve clinical trialsE-posterART in first- and second-line therapies
B32Long-term analysis of B/F/TAF in treatment-naïve adults living with HIV through four years of follow-upE-posterART in first- and second-line therapies
B33Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study)Oral abstract session with live Q&AART in highly treatment-experienced people
B33Transition to TLD leads to decreased rates of virologic failure among PLWH in sub-Saharan AfricaE-posterART in highly treatment-experienced people
B33Long-term (96-week) safety of fostemsavir (FTR) in heavily treatment-experienced (HTE) adults infected with multidrug-resistant (MDR) HIV-1 (BRIGHTE Phase 3 study)E-posterART in highly treatment-experienced people
B33Weight changes in HIV+ individuals receiving ibalizumab over 96 weeksE-posterART in highly treatment-experienced people
181 - 190 of 870 items